Preliminary data from a 4-year mirror-image and multicentre study of patients initiating paliperidone palmitate 6-monthly long-acting injectable antipsychotic: the Paliperidone 2 per Year study.
Juan Antonio García-CarmonaAlba García-PérezGuillermo Isidro GarcíaLuis Alberto Forcen-MuñozSantiago Ovejero GarcíaRocío Sáez PovedanoAna Luisa González-GaldámezLaura Mata IturraldeFernando Hernández-SánchezMariluz Ramirez BonillaPaloma Fuentes-PérezClaudia Ovejas-CatalánPaula Suárez-PinillaFrancisco Valdivia-MuñozBlanca Fernández AbascalMiguel Omaña ColmenaresÁngela de Lourdes Martín-PérezMaría Pilar Campos-NavarroEnrique Baca-GarcíaSergio Benavente-LópezAlberto Raya PlateroMiguel Barberán NavalónSergio Sánchez-AlonsoJavier Vázquez-BourgonSofia PappaPublished in: Therapeutic advances in psychopharmacology (2023)
Patient and clinician preference for LAIs with longer dosing intervals was the main reason for PP6M initiation/switching resulting in high treatment persistence. Future data are needed to evaluate the full impact of PP6M in clinical practice.